Abstract
Introduction: Nano drug delivery is a broad field of research on the development of novel nano- carrier systems for effective therapeutic delivery of drugs. Here, an anticancer drug, cisplatin (CDDP) conjugated Gold Nanoparticles (GNPs) via L-Lysine (Lys) linker.
Methods: The produced nanodrug (GNPs-Lys-CDDP) was characterized by UV-Vis spectroscopy, Dynamic Light Scattering (DLS), Zeta potentials and electron force microscopy. The cytotoxic efficacy of the GNPs-Lys-CDDP against human breast cancer cells (SKBR3) and normal cells (MCF- 10A) was evaluatedby MTT assay. Cell apoptosis and morphology changes were assessed by flowcytometery and Acridine Orange/Ethidium Bromide (AO/EtBr) staining, respectively.
Results: It was found that the GNPs-Lys-CDDP with a size of 85 nm and negatively charged with a zeta-potential of about -25 mV could be taken up by tumor cells. A marked change in the UV spectrum of GNPs-Lys-CDDP compare to GNPs showed a strong absorption shift in the 525 nm region. The LD 50 of GNPs-Lys-CDDP against SKBR3 (1 μg.mL -1), was found to be 8 times lower than that of naked CDDP against SKBR3 (8 μg.mL -1). The nanocomplex GNPs-Lys-CDDP also significantly increased the apoptosis of SKBR3 with the lowest cytotoxic effects on normal cells.
Discussion: This work indicates that GNPs effectively could decrease the lethal dose of CDDP to 87%. Hence, GNPs modified by Lys, could be a good nano-carrier for chemotherapeutic drugs.
Keywords: Drug delivery, gold nanoparticles, cancer treatment drug, l-lysine, cisplatin, spectroscopy.
Graphical Abstract
[http://dx.doi.org/10.1016/j.jare.2010.02.002]
[http://dx.doi.org/10.1016/j.msec.2018.10.008] [PMID: 30423769]
[http://dx.doi.org/10.1038/s41598-018-32756-w] [PMID: 30348974]
[http://dx.doi.org/10.1016/j.physleta.2017.10.042]
[http://dx.doi.org/10.1002/mabi.200600075] [PMID: 16921538]
[http://dx.doi.org/10.1016/j.imlet.2017.07.015] [PMID: 28760499]
[http://dx.doi.org/10.1002/anie.200904359] [PMID: 20401880]
[http://dx.doi.org/10.1002/wnan.1390] [PMID: 26848041]
[http://dx.doi.org/10.1039/b914071a]
[http://dx.doi.org/10.1039/c2cc30679d] [PMID: 22441353]
[http://dx.doi.org/10.1016/j.biomaterials.2011.09.064] [PMID: 22036101]
[http://dx.doi.org/10.1016/j.colsurfb.2014.08.021] [PMID: 25216919]
[http://dx.doi.org/10.1021/bc9002212] [PMID: 19919059]
[http://dx.doi.org/10.1021/mp5007163] [PMID: 25587849]
[http://dx.doi.org/10.1038/s41598-017-18938-y] [PMID: 29330486]
[http://dx.doi.org/10.2147/IJN.S214467] [PMID: 31564860]
[http://dx.doi.org/10.3390/cancers3011351] [PMID: 24212665]
[http://dx.doi.org/10.18632/oncotarget.2203] [PMID: 25071019]
[http://dx.doi.org/10.1021/jp061667w] [PMID: 16898714]
[http://dx.doi.org/10.1007/978-1-61779-080-5_20]
[http://dx.doi.org/10.1039/c2an36467k] [PMID: 23304695]
[http://dx.doi.org/10.1111/jphp.13098] [PMID: 31049986]